Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Evia Bio logo — Better and Safer Therapeutics Enabled by All-Natural Cryopre...

Evia Bio

Better and Safer Therapeutics Enabled by All-Natural Cryopreservation.

Founded 2019 United States Minneapolis, United States 11 employees Private Equity Total: $260.00K Biotechnology, Health and Wellness +1

General Information

Company Name Evia Bio
Founded Year 2019
Location United States Minneapolis, United States
Employees 11
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Evia Bio. To contact Evia Bio, visit eviabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Evia Bio compare?

A PDF of Evia Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Evia Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Evia Bio

Evia Bio is a biotechnology startup founded in 2019 and headquartered in the United States. The company's slogan, "Better and Safer Therapeutics Enabled by All-Natural Cryopreservation," reflects its commitment to developing innovative solutions for the growing cell therapy market. Evia Bio collaborates with cell therapy companies to advance products to clinical trials and commercialization by providing non-DMSO cryopreservation solutions developed by cryobiologist Allison Hubel, PhD. The solutions employ all-natural organic compounds to safeguard cell integrity during cryopreservation and ensure patient safety at the point of care. Evia Bio's approach to cryopreservation offers a promising alternative to traditional methods, potentially unlocking the full potential of life-saving therapies. The company recently secured a Private Equity Round investment on 01 January 2024, with the investment coming from Pleasant Bay Capital Partners. This injection of funding signifies external validation of Evia Bio's potential and could propel the company towards further growth and impact in the biotechnology and cell therapy sectors. For more information, please visit www.eviabio.com.

Business keywords: Life Science Innovation, Cell Therapy, Cryopreservation, Therapeutics, Clinical Trials, Commercialization, Biopharmaceuticals, Organic Compounds, Cell Integrity, Patient Safety, Gene Therapy, Biomedical Research, Bioengineering, Medical Innovations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 1
Pleasant Bay Capital Partners
Pleasant Bay Capital Partners
01 Jan 2024
Grant $10.00K 1
Walleye Tank
06 Dec 2022
Series A $250.00K 1
Newchip Accelerator
30 Jun 2022

Evia Bio Alternatives & Competitors

View All Alternatives
Evia Bio vs
ImmunAbs Inc.
ImmunAbs Inc.

ImmunAbs Inc. is Specialized Antibody Pharmaceutical Development Biotech Venture. "Hope for Patient...

Series B
11 employees
Biotechnology, Health Care
Evia Bio vs
ProtaGene
ProtaGene Germany

Analytic services for biologics and cell therapies

Growth
130 employees
Biopharma, Biotechnology
Evia Bio vs
Excision BioTherapeutics
Excision BioTherapeutics United States

Developing CRISPR-based therapies intended to cure viral infectious diseases.

Grant
24 employees
Biotechnology, Health Care
View all alternatives

FAQ About Evia Bio

Better and Safer Therapeutics Enabled by All-Natural Cryopreservation.
Evia Bio was founded in 2019.
Evia Bio is headquartered in Minneapolis, United States.
Evia Bio operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on Life Science Innovation, Cell Therapy, Cryopreservation and Therapeutics.
Evia Bio has approximately 11 employees.
Evia Bio has completed 3 funding rounds, raising a total of $260.00K. The latest funding stage is Private Equity.
Top alternatives and competitors to Evia Bio include ImmunAbs Inc., ProtaGene, Excision BioTherapeutics, Benitec Biopharma Inc., Alphyn Biologics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Evia Bio and ImmunAbs Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evia Bio, https://bouncewatch.com/company/evia-bio, updated 14 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes